RecruitingNCT05282108
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Studying Congenital generalized lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hikma Pharmaceuticals LLC
- Intervention
- Carcemia(drug)
- Enrollment
- 240 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (4)
- National Cancer Institute (NCI), Cairo, Egypt
- Ain Shams University Hospital, Cairo, Egypt
- Nasser Institute, Cairo, Egypt
- Tanta Oncology Center, Tanta, Egypt
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05282108 on ClinicalTrials.govOther trials for Congenital generalized lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06390306The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBPPeking University People's Hospital
- ACTIVE NOT RECRUITINGNCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in FranceNovartis Pharmaceuticals
- RECRUITINGNCT05682924Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation BosutinibSamara State Medical University
- RECRUITINGPHASE2NCT05143840Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseAugusta University
- RECRUITINGPHASE1, PHASE2NCT04925479Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT04626024Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationBaylor College of Medicine
- RECRUITINGPHASE1, PHASE2NCT03934372Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsIncyte Biosciences International Sàrl
- ACTIVE NOT RECRUITINGPHASE2NCT03516279Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseECOG-ACRIN Cancer Research Group